Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE R&D

R&D at other companies

Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Amgen logo
AmgenAMGN
$1.72B+15.7%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$228.9M+1.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$173.25M+30.2%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$68.57M-5.4%
Moderna logo
ModernaMRNA
$649M-24.2%

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's R&D?
Ultragenyx Pharmaceutical (RARE) reported R&D of $187M in Q1 2026.
How has Ultragenyx Pharmaceutical's R&D changed year-over-year?
Ultragenyx Pharmaceutical's R&D increased by 12.7% year-over-year, from $166M to $187M.
What is the long-term trend for Ultragenyx Pharmaceutical's R&D?
Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's R&D has grown at a 10.8% compound annual growth rate (CAGR), from $497.15M to $750.23M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.